Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/ Wnt/β-catenin signaling axis.
Zhaobo ChengRenjie YuLi LiJunhao MuYijia GongFan WuYujia LiuXiangyi ZhouXiaohua ZengYongzhong WuRan SunTing-Xiu XiangPublished in: Cellular and molecular life sciences : CMLS (2022)
Zinc-finger proteins (ZNFs) constitute the largest transcription factor family in the human genome. The family functions in many important biological processes involved in tumorigenesis. In our research, we identified ZNF334 as a novel tumor suppressor of triple-negative breast cancer (TNBC). ZNF334 expression was usually reduced in breast cancerv (BrCa) tissues and TNBC cell lines MDA-MB-231 (MB231) and YCCB1. We observed that promoter hypermethylation of ZNF334 was common in BrCa cell lines and tissues, which was likely responsible for its reduced expression. Ectopic expression of ZNF334 in TNBC cell lines MB231 and YCCB1 could suppress their growth and metastatic capacity both in vitro and in vivo, and as well induce cell cycle arrest at S phase and cell apoptosis. Moreover, re-expression of ZNF334 in TNBC cell lines could rescue Epithelial-Mesenchymal Transition (EMT) process and restrain stemness, due to up-regulation of SFRP1, which is an antagonist of Wnt/β-catenin signaling. In conclusion, we verified that ZNF334 had a suppressive function of TNBC cell lines by targeting the SFRP1/Wnt/β-catenin signaling axis, which might have the potentials to become a new biomarker for diagnosis and treatment of TNBC patients.
Keyphrases
- poor prognosis
- epithelial mesenchymal transition
- transcription factor
- stem cells
- cell proliferation
- gene expression
- cell cycle arrest
- binding protein
- dna methylation
- end stage renal disease
- squamous cell carcinoma
- endothelial cells
- small cell lung cancer
- ejection fraction
- long non coding rna
- newly diagnosed
- chronic kidney disease
- transforming growth factor
- pi k akt
- genome wide
- breast cancer risk
- breast cancer cells